A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
First received: December 7, 2009
Last updated: May 18, 2015
Last verified: May 2015
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.

Condition Intervention Phase
Drug: nilotinib (AMN107)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Clinical efficacy of nilotinib based on overall response rate (ORR) [ Time Frame: study period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Durable overall response rate (ORR) of patients treated with nilotinib [ Time Frame: study period ] [ Designated as safety issue: No ]
  • Progression free survival (PFS) of patients treated with nilotinib [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Overall survival (OS) of patients treated with nilotinib [ Time Frame: study period ] [ Designated as safety issue: No ]

Enrollment: 55
Study Start Date: June 2010
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AMN107 (nilotinib) Drug: nilotinib (AMN107)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. Histologically confirmed mucosal or acral 2. Presence of a c-Kit mutation of exon 9, 11 or 13, or mutations Y822D and mutations D820Y, Y823D of exon 17, as confirmed by the central laboratory 3. Stage III unresectable or stage IV disease 4. The presence of one or more measurable lesions as detected by radiological or photographic methods and assessed according to RECIST 1.0. Lesions must have a size of at least 10mm at longest diameter (using a slice thickness of 5 mm)or double the slice thickness to be considered a target lesion. Target lesions should not be selected in previously irradiated fields unless there is clear evidence of progression 5. WHO performance status 0 - 2

Exclusion Criteria:

  1. C-Kit mutation of exons 17(except mutations D820Y, Y822D or Y823D) or any other exon not allowed by the inclusion criteria
  2. Patients with c-Kit amplifications only and no mutation
  3. Patients with any history of brain metastases
  4. Patients who have had any prior treatment with TKIs
  5. Patients receiving medications or herbal extracts which interfere with nilotinib metabolism which are not discontinued by the time of the baseline visit

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01028222

  Hide Study Locations
United States, California
City of Hope National Medical Center City of Hope national Med Ctr
Duarte, California, United States, 91010-3000
University of California San Diego UCSD Moores Cancer Center
La Jolla, California, United States, 92093-0658
University of California at Los Angeles UCLA
Los Angeles, California, United States, 90024
California Pacific Medical Center California Pacific Med
San Francisco, California, United States, 94120-7999
United States, Colorado
University of Colorado Univ Colorado 2
Aurora, Colorado, United States, 80045
United States, Illinois
Rush University Medical Center SC
Chicago, Illinois, United States, 60612
Oncology Specialists, SC Dept.of Oncology Specialists
Park Ridge, Illinois, United States, 60068-0736
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Dana Farber Cancer Institute DFCI - Brookline
Boston, Massachusetts, United States, 02115
United States, Minnesota
Mayo Clinic - Rochester Mayo Clinic- Gonda
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University School of Medicine CAMN107B2301
St. Louis, Missouri, United States, 63110
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
United States, Ohio
Case Western Reserve Case Western
Cleveland, Ohio, United States, 44106-5000
United States, Texas
Baylor Health Care System/Sammons Cancer Center Baylor 2
Dallas, Texas, United States, 75246
Novartis Investigative Site
Buenos Aires, Argentina, C1125ABE
Australia, New South Wales
Novartis Investigative Site
North Sydney, New South Wales, Australia, 2060
Australia, South Australia
Novartis Investigative Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Novartis Investigative Site
Parkville, Victoria, Australia, 3050
Novartis Investigative Site
Brussel, Belgium, 1090
Novartis Investigative Site
Bruxelles, Belgium, 1200
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
Belo Horizonte, MG, Brazil, 30150-281
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 20230-130
Novartis Investigative Site
São Paulo, SP, Brazil, 01246-000
Canada, Ontario
Novartis Investigative Site
Toronto, Ontario, Canada, M4N 3M5
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 2M9
Novartis Investigative Site
Beijing, China, 100036
Novartis Investigative Site
Erlangen, Germany, 91054
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
Köln, Germany, 50937
Novartis Investigative Site
Muenchen, Germany, 80336
Novartis Investigative Site
Tübingen, Germany, 72076
Novartis Investigative Site
Meldola, FC, Italy, 47014
Novartis Investigative Site
Genova, GE, Italy, 16132
Novartis Investigative Site
Milano, MI, Italy, 20141
Novartis Investigative Site
Milano, MI, Italy, 20133
Novartis Investigative Site
Padova, PD, Italy, 35100
Novartis Investigative Site
Siena, SI, Italy, 53100
Novartis Investigative Site
Amsterdam, Netherlands, 1081 HV
Novartis Investigative Site
Nijmegen, Netherlands, 6525 GA
Novartis Investigative Site
Singapore, Singapore, 169610
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08036
Novartis Investigative Site
Hospitalet de LLobregat, Cataluña, Spain, 08907
Novartis Investigative Site
Goteborg, Sweden, SE-413 45
Novartis Investigative Site
Malmö, Sweden, SE-205 02
Novartis Investigative Site
Stockholm, Sweden, SE-171 76
Novartis Investigative Site
Uppsala, Sweden, SE-751 85
Novartis Investigative Site
Zürich, Switzerland, 8091
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Additional Information:
No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01028222     History of Changes
Other Study ID Numbers: CAMN107B2301, 2009-015514-21
Study First Received: December 7, 2009
Last Updated: May 18, 2015
Health Authority: United States: Food and Drug Administration
Argentina: Ministry of Health
Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Brazil: National Health Surveillance Agency
Canada: Health Canada
China: Food and Drug Administration
Germany: Federal Institute for Drugs and Medical Devices
Italy: National Institute for Health
Netherlands: Medicines Evaluation Board (MEB)
Poland: Ministry of Health
Singapore: Health Sciences Authority
Spain: Ministry of Health
Sweden: Medical Products Agency
Switzerland: Swissmedic
Thailand: Food and Drug Administration

Keywords provided by Novartis:
c-Kit mutated metastatic and/or inoperable melanoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on November 25, 2015